Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and Anti-VEGF treatment

Neoplasia

Volumn 13, Issue 5, 2011, Pages 419-427

  Starlinger, Patrick ^a   Brugger, Philipp ^a   Schauer, Dominic ^a   Sommerfeldt, Silvia ^a   Tamandl, Dietmar ^a   Kuehrer, Irene ^a   Schoppmann, Sebastian F ^a   Gnant, Michael ^a   Brostjan, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CA 19-9 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBOSPONDIN 1; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PATIENT; CELL MOTILITY; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

EID: 79955863129     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101508     Document Type: Article

References (40)

1. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
2. Kilarski WW and Bikfalvi A (2007). Recent developments in tumor angiogenesis. Curr Pharm Biotechnol 8, 3-9.
3. Verheul HM and Pinedo HM (2003). Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc) 39(suppl C), 81-93.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355, 2542-2550.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357, 2666-2676.
7. Gasparini G, Longo R, Fanelli M, and Teicher BA (2005). Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23, 1295-1311.
8. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, et al. (2009). Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27, 2231-2237.
9. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol 28, 3617-3622.
10. Baeriswyl V and Christofori G (2009). The angiogenic switch in carcinogenesis. Semin Cancer Biol 19, 329-337.
11. Karayiannakis AJ, Bolanaki H, Syrigos KN, Asimakopoulos B, Polychronidis A, Anagnostoulis S, and Simopoulos C (2003). Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 194, 119-124.
12. Seo Y, Baba H, Fukuda T, Takashima M, and Sugimachi K (2000). High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88, 2239-2245.
13. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, et al. (1999). Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59, 5209-5218.
14. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, and Fidler IJ (2001). Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16, 359-370.
15. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, et al. (2008). Rapid chemotherapyinduced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263-273.
16. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, et al. (2006). Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12, 557-567.
17. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, et al. (2004). Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10, 64-71.
18. Roodhart JM, Langenberg MH, Vermaat JS, Lolkema MP, Baars A, Giles RH, Witteveen EO, and Voest EE (2010). Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients. Neoplasia 12, 87-94.
19. Brostjan C, Bayer A, Zommer A, Gornikiewicz A, Roka S, Benko T, Yaghubian R, Jakesz R, Steger G, Gnant M, et al. (2003). Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy. Cancer 98, 2291-2301.
20. Brostjan C, Gebhardt K, Gruenberger B, Steinrueck V, Zommer H, Freudenthaler H, Roka S, and Gruenberger T (2008). Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Clin Cancer Res 14, 2065-2074.
21. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, et al. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23, 8136-8139.
22. Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, and Bocci G (2007). Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25, 1816-1818.
23. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, et al. (2009). Platelets actively sequester angiogenesis regulators. Blood 113, 2835-2842.
24. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr, and Ryeom S (2010). Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115, 4605-4613.
25. Eskens FA and Sleijfer S (2008). The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 44, 2350-2356.
26. Brufsky A, Rivera RR, Hurvitz SA, Bondarenko IN, Smirnov V, Valero V, Rugo HS, Swamy R, Mu H, and Perez EA (2010). Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (ASCO Annual Meeting Proceedings) 28. Abstract 1021.
27. MarkmanM (2003).Managing taxane toxicities. SupportCare Cancer 11, 144-147.
28. Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, et al. (2010). First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8, 71.
29. Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, and Nemunaitis J (2000). Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am J Clin Oncol 23, 463-472.
30. Kitayama J, Yasuda K, Kawai K, Sunami E, and Nagawa H (2010). Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol 5, 47.
31. Saif MW, Choma A, Salamone SJ, and Chu E (2009). Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 101, 1543-1552.
32. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15, 2403-2413.
33. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, et al. (1999). Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17, 2341-2354.
34. Joensuu H, Sailas L, Alanko T, Sunela K, Huuhtanen R, Utriainen M, Kokko R, Bono P, Wigren T, Pyrhonen S, et al. (2010). Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol 21, 968-973.
35. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, et al. (2008). Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26, 3950-3957.
36. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27, 1227-1234.
37. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. (2010). Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21, 1804-1809.
38. Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann SF, Gnant M, et al. (2010). Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vivo processes. J Thromb Haemost 8, 1809-1819.
39. Kazerounian S, Yee KO, and Lawler J (2008). Thrombospondins in cancer. Cell Mol Life Sci 65, 700-712.
40. Bocci G, Francia G, Man S, Lawler J, and Kerbel RS (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100, 12917-12922.